Clinical Trial Update: Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer [Phase 2]

View source ↗

Summary

Phase II clinical trial exploring QL1706 in combination with paclitaxel and bevacizumab for second-line treatment of gastric cancer; recruitment not yet started…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)
• QL1706

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Gastric Cancer (GC) | Phase 2 | Status: NOT_YET_RECRUITING